Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) has been given a consensus rating of “Buy” by the eight analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among analysts that […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) saw a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 2,180,000 shares, a drop of 18.0% from the April 15th total of 2,660,000 shares. Based on an average daily volume of 277,300 shares, the days-to-cover ratio is […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Rating) announced its earnings results on Wednesday. The company reported ($0.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.05), MarketWatch Earnings reports. NASDAQ:CRNX traded up $2.26 during midday trading on Thursday, hitting $21.26. The company’s stock had a trading volume of 9,232 shares, compared to […]
Equities research analysts expect that Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) will report earnings per share of ($0.57) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Crinetics Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.62) and the highest estimate coming in at ($0.51). Crinetics […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) has been given an average rating of “Buy” by the seven brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among […]